Morgan Stanley set a €92.00 ($108.24) price target on Sanofi SA (EPA:SAN) in a report published on Friday. The firm currently has a buy rating on the stock.

A number of other research analysts have also recently commented on SAN. UBS AG set a €82.00 ($96.47) price objective on Sanofi SA and gave the company a neutral rating in a report on Wednesday, June 14th. Jefferies Group LLC set a €90.00 ($105.88) price objective on Sanofi SA and gave the company a neutral rating in a report on Friday, June 16th. J P Morgan Chase & Co set a €95.00 ($111.76) price objective on Sanofi SA and gave the company a neutral rating in a report on Thursday, June 22nd. Credit Suisse Group set a €95.00 ($111.76) price target on Sanofi SA and gave the stock a buy rating in a research note on Tuesday, July 4th. Finally, Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price target on Sanofi SA and gave the stock a neutral rating in a research note on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of €87.88 ($103.39).

Sanofi SA (SAN) opened at 86.05 on Friday. Sanofi SA has a one year low of €24.55 and a one year high of €86.39. The firm has a 50 day moving average of €26.11 and a 200-day moving average of €26.01. The firm has a market cap of €108.06 billion and a price-to-earnings ratio of 12.00.

TRADEMARK VIOLATION WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/sanofi-sa-san-given-a-92-00-price-target-at-morgan-stanley/1620542.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with Analyst Ratings Network's FREE daily email newsletter.